リーシュマニア症(カラアザール)治療薬の世界市場:治験レビュー

【英語タイトル】Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H2, 2019

GlobalDataが出版した調査資料(GDT20FB0046)・商品コード:GDT20FB0046
・発行会社(調査会社):GlobalData
・発行日:2019年12月
・ページ数:153
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品およびヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H2, 2019″ provides an overview of Leishmaniasis (Kala-Azar) clinical trials scenario. This report provides top line data relating to the clinical trials on Leishmaniasis (Kala-Azar) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profile Snapshots 33
Appendix 153
Abbreviations 153
Definitions 153
Research Methodology 154
Secondary Research 154
About GlobalData 155
Contact Us 155
Source 156

List of Tables
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Region, 2019* 7
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Europe, Top Countries, 2019* 12
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 14
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 15
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, G7 Countries (%), 2019* 16
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, E7 Countries (%), 2019* 19
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Phase, 2019* 22
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Leishmaniasis (Kala-Azar) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 31
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 32

List of Figures
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Region (%), 2019* 7
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 8
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Europe, Top Countries (%), 2019* 12
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 14
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 15
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, G7 Countries (%), 2019* 16
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, E7 Countries (%), 2019* 19
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Leishmaniasis (Kala-Azar) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 32
GlobalData Methodology 154

★調査レポート[リーシュマニア症(カラアザール)治療薬の世界市場:治験レビュー] (コード:GDT20FB0046)販売に関する免責事項を必ずご確認ください。
★調査レポート[リーシュマニア症(カラアザール)治療薬の世界市場:治験レビュー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆